Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Feb 11, 2026
- Amount
- $500,000
- Closes
- May 25, 2027 (in 241 days)
Similar opportunities open now
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Nov 2029Up to $600K
- Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 2028
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Oct 19, 2026 (in 23 days)Up to $600K
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 9, 2026 (in 44 days)
Classification and identifiers
- Solicitation number
- PAR-28-057
- Assistance listing (CFDA)
- 93.393
Amount
$500,000
Who can apply
Nonprofits, including small and volunteer-run organizations and Local government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) is soliciting applications for the establishment of the Management and Data Coordination Unit (MDCU), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC). The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma and conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC-MDCU will provide support toward collaborative efforts such as: study design, protocol development, statistical analysis, coordin...